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Abstract We previously reported that in a diabetes mouse
model,characterisedbymoderatehyperglycaemiaandreduced
β-cell mass, the radical scavenger bis(1-hydroxy-2,2,6,6-
tetramethyl-4-piperidinyl)decandioate di-hydrochloride
(IAC), a non-conventional cyclic hydroxylamine derivative,
improves metabolic alterations by counteracting β-cell dys-
function associated with oxidative stress. The aims of this
study were to ascertain whether the beneficial effects of IAC
treatment could be maintained after its discontinuation and
further elucidate the underlying mechanisms. Diabetes was
induced in C57Bl/6J mice by streptozotocin (STZ) and
nicotinamide (NA) administration. Diabetic mice were treated
for 7 weeks with various doses of IAC (7.5, 15, or 30 mg/kg b.
w./die i.p.) and monitored for additional 8 weeks after
suspension of IAC. Then, pancreatic tissue was used for
determinationofβ-cellmassbyimmunohistochemistryandβ-
cell ultrastructural analysis. STZ-NA mice showed moderate
hyperglycaemia, glucose intolerance and reduced β-cell mass
(25% ofcontrols). IAC-treated STZ-NA mice(at both doses of
15 and 30 mg/kg b.w.) showed long-term reduction of
hyperglycaemia even after discontinuation of treatment,
attenuation of glucose intolerance and partial preservation of
β-cell mass. The lowest IAC dose was much less effective.
Plasma nitrotyrosine levels (an oxidative stress index) signif-
icantly increased in untreated diabetic mice and were lowered
upon IAC treatment. At ultrastructural level, β cells of IAC-
treated diabetic mice were protected against degranulation and
mitochondrial alterations. In the STZ-NA diabetic mouse
model, the radical scavenger IAC induces a prolonged
reduction of hyperglycaemia associatedwith partial restoration
of β-cell mass and function, likely dependent on blockade of
oxidative stress-induced damaging mechanisms.
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Introduction
Type 2 diabetes (T2D) is characterised by a combination of
peripheral insulin resistance and defective insulin secretion
(Kahn 2003). Usually, the disease arises due to the
progressive failure of insulin secretion by β cells to overcome
reduced sensitivity to the hormone (Kahn 2001;P r e n t k ia n d
Nolan 2006). This leads to hyperglycaemia, which can in turn
exert deleterious effects on β cells (Robertson 2004). Among
the various mechanisms likely responsible for β-cell dys-
function and damage induced by hyperglycaemia, oxidative
stress is considered to play a major role (Kaneto et al. 2005;
Prentki and Nolan 2006; Robertson 2004).
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DOI 10.1007/s00210-010-0524-7Actually, in T2D, increased plasma glucose levels, often
associated with high circulating free fatty acid (FFA) concen-
trations, result in enhanced mitochondrial superoxide produc-
tionandincreasedexposureofcellstoreactiveoxygenspecies
(ROS) (Brownlee 2003;L o w e l la n dS h u l m a n2005), which
can also be generated through the glycation reaction (Kaneto
et al. 1996) and the hexosamine pathway (Kaneto et al.
2001). Moreover, the enhanced superoxide production is
usually accompanied by increased NO generation due to
induction of NO synthase (Beckman and Koppenol 1996).
Thisfavoursthe productionofradical nitrogenspecies (RNS),
such as the cytotoxic peroxynitrite anion, which in turn
oxidises sulfhydryl groups in proteins, nitrates amino acids
like tyrosine, aggravates lipid peroxidation and provokes
DNA strand breaks, eventually leading to severe cell damage
(Beckman and Koppenol 1996). It should also be considered
that β cells are especially sensitive to ROS excess because of
a low expression of ROS-detoxifying enzymes in compari-
son with other cell types (Tiedge et al. 1997).
We previously tested the protective effects of a low
molecular weight radical scavenger, namely, bis(1-hydroxy-
2,2,6,6-tetramethyl-4-piperidinyl)decandioate di-hydrochloride
(IAC), in a non-obese diabetes mouse model characterised by
reduced pancreatic insulin content and moderate hyperglycae-
mic levels, like those usually occurring in human T2D. This
model, obtained by the combined administration of strepto-
zotocin (STZ) and nicotinamide (NA), has been developed in
o u rl a b o r a t o r ya sw e l la si no t h e r s( M a s i e l l oe ta l .2006;
Matsuyama-Yokono et al. 2008;N a k a m u r ae ta l .2006)a n d
is increasingly used for pharmacological research in diabetes
(Novelli et al. 2007; Tahara et al. 2008, 2009). In STZ-NA
mice, IAC was able to reduce hyperglycaemia and partially
preserve pancreatic insulin content, thus counteracting β-cell
dysfunction associated with oxidative stress (Novelli et al.
2007). IAC is a non-conventional cyclic hydroxylamine
derivative antioxidant synthesised in our laboratories (for its
chemical structure, see Fig. 1). It is hydrosoluble in its
protonated chloridrate form, membrane permeant and acts as
an effective and self-regenerating intracellular scavenger of
most oxygen, nitrogen and carbon-centred radicals at an
early stage, i.e. prior to the generation of ROS- and RNS-
derived toxic products (Valgimigli et al. 2001). The aims of
the present study were (1) to ascertain whether the beneficial
effects of IAC in diabetic mice could be maintained after
discontinuation of the treatment and (2) to provide further
insights into the mechanisms of its protective effect.
Materials and methods
Animals
Experiments were performed in male C57Bl/6J mice, of the
age of 8–9 weeks, weighing 22–24 g, purchased from Harlan
Laboratories s.r.l. (S. Pietro al Natisone, Udine, Italy). Mice
were kept at a constant temperature of 24–25°C and were
subjected to a controlled 12 h light–dark cycle; they had free
access to water and pelleted diet. The experimental protocol
followed the Principles of Laboratory Animal Care (US NH
publication no. 83-85, revised 1985) and was approved by the
Ethical Committee of the University of Pisa.
Induction of diabetes
Nicotinamide (210 mg/kg b.w.) (Sigma, Saint Louis, MO,
USA), dissolved in saline, was injected intraperitoneally
15 min before administration of STZ (Sigma, 180 mg/kg b.
w., i.p.), which was dissolved in buffer citrate (pH 4.5)
immediately before use. Controls received both vehicles.
During the experimental period, the animals’ food intake
and body weight were monitored once a week.
IAC treatment
Glycaemia was measured 7, 14, and 21 days after STZ-NA
treatment to assess stability of glycaemic values, and on the
22nd day, diabetic mice were homogeneously distributed
into four subgroups of 10–12 mice each. Pharmacological
treatment was randomly assigned to the four diabetic
groups, three of them receiving intraperitoneal administra-
tion of IAC at the dosage of 7.5, 15 or 30 mg/kg b.w./day
respectively, dissolved in saline immediately before use and
the fourth receiving saline only. Two groups of non-diabetic
controls were administered daily either saline or 30 mg/kg
IAC i.p. IAC was synthesised in our laboratory, as detailed
elsewhere (Valgimigli et al. 2001). After 7 weeks of
treatment, IAC administration was discontinued, and mice
were monitored for an additional 8-week period. Then,
3-h fasted animals were anaesthetised using pentobarbital
(50 mg/kg b.w., i.p.), and the pancreas was rapidly
removed, dissected free of fat and processed for immuno-
histochemical and electron microscope analyses.
Assays in whole blood or plasma
Blood sampling was performed in conscious mice that had
food removed 3 h earlier, unless otherwise specified.
Fig. 1 Chemical structure of bis(1-hydroxy-2,2,6,6-tetramethyl-4-
piperidinyl)decandioate (IAC), showing the two opposite cyclic
hydroxylamine moieties linked by a long aliphatic chain
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blood obtained by cutting the tip of the tail, using
OneTouch Ultra glucometer apparatus (Life Scan, Inc.,
Milpitas, CA, USA). When required (e.g., for plasma
insulin or nitrotyrosine measurements), some drops of
blood (80–100 μl) were collected by the same method in
small tubes containing 2 μl of concentrated EDTA. Plasma
was separated by centrifugation and stored at −20°C until
assayed. Plasma insulin was measured by radioimmunoas-
say according to Herbert et al. (1965), using a guinea pig
insulin antibody from ICN (Costa Mesa, CA, USA) and
125I-labeled insulin from LINCO (LINCO Research, St.
Charles, MO, USA). Plasma nitrotyrosine concentration
was determined using a commercially available kit (Nitro-
tyrosine Assay Kit, Upstate, Lake Placid, NY, USA).
Intraperitoneal glucose tolerance test
After 6 weeks of IAC treatment, glucose (1.5 g/kg b.w.,
administeredintraperitoneallyas16.5%solution)wasgivento
3-h fasted conscious animals. Blood samples were obtained
sequentially from the tail vein before and after the glucose
injectionandimmediatelyusedforglucosedeterminationbya
glucometer or collected in EDTA-treated small tubes and
centrifuged at 4°C (0-, 15- and 60-min samples), with storage
of plasma at −20°C for subsequent insulin measurement. The
daily IAC dose was administered at the end of the test.
Immunohistochemistry
Tissue preparation For evaluation of morphological aspects
and measurement of β-cell mass, 26 pancreases were
included in this study, removed from the following groups
of mice: controls (n=6); STZ-NA untreated diabetics (n=
6); 7.5 mg/kg IAC-treated (n=4); 15 mg/kg IAC-treated
(n=5); 30 mg/kg IAC-treated (n=5) diabetics. Each
pancreas was cleared of fat and lymph nodes and weighed.
A suitable fragment taken from the pancreatic tail was fixed
in 10% buffered formalin and processed using the standard
procedure to obtain a paraffin-embedded tissue block.
Immunohistochemical staining Paraffin sections (2-μm
thickness) were mounted on treated slides (two to three
sections per slide) and dried in oven at 56°C for 20 min.
After progressive hydration, the sections were incubated
with a guinea pig anti-insulin polyclonal antibody (Zymed
Laboratories, San Francisco, CA, USA), and immunoreac-
tivity was visualised as a brown cytoplasmic staining by the
kit Histomouse (Zymed Laboratories) containing diamino-
benzidine chromogen. Negative controls were incubated in
phosphate-buffered saline instead of primary antibody.
Finally, the nuclei were stained in blue by haematoxylin,
and the sections were submitted to morphometric analysis.
Morphometric analysis Morphometric analysis was per-
formed by a BX-51 Olympus microscope connected to a
computer by a color CCD camera. The analySIS
B software
(Olympus) was used to acquire images at different
magnifications. In this way, we were able to obtain
measurements in micrometre by the inside calibrator, and
data were normalised per surface unit (square millimetre).
The colorimetric property of the system was able to
recognise and quantify the total section area (blue color +
brown color), the total islet surface after selection of the
perimeter of each islet present in the specimen and the
insulin-positive area (brown color). The set-up of brown
and blue colors was done using the staining of the
corresponding control group. The average β-cell area
measured in each pancreas specimen was used to calculate
β-cell mass by multiplying it by the weight of the
corresponding pancreas. In addition, the islet number was
determined on each section by the computerised program
and expressed per surface unit (square millimetre).
Electron microscopy
Pancreatic samples were fixed with 2.5% (vol./vol.)
glutaraldehyde in 0.1 mmol/l phosphate buffer, pH 7.4,
for 2 h at 4°C, and then postfixed in 1% (vol./vol.)
phosphate-buffered osmium tetroxide for 30 min at 4°C.
Samples were dehydrated in a graded series of ethanol,
transferred to propylene oxide and embedded in PolyBed
812 (Polysciences Inc.). Ultrathin sections (60–80 nm
thick) were cut with a diamond knife, placed on copper
grids (200 mesh), stained with uranyl acetate and lead
citrate and observed with a Zeiss 902 electron microscope.
Morphometric analyses were performed as previously
described (Marchetti et al. 2004). Micrographs, obtained
at ×10,000, were analysed by overlay with a graticule (11×
11 cm) composed of 169 points. For the study of beta
granules and mitochondria, volume density was calculated
according to the formula: volume density = Pi/Pt, where Pi
is the number of points within the subcellular component
and Pt is the total number of points, and expressed as ml/
100 ml tissue (ml%). Three to four islets per pancreas were
studied, and 20–25 β cells per islet were analysed in non-
diabetic controls (n=3), untreated diabetic (n=4) and
30 mg/kg IAC-treated diabetic mice (n=4).
Statistical analysis
All data are presented as means ± SEM. Statistical
significance was evaluated by analysis of variance
(ANOVA) followed by Tukey post hoc test for multiple
comparisons. A p<0.05, at least, was considered as
significant.
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Time course of glycaemic levels As shown in Fig. 2,
3-h fasted STZ-NA mice showed high blood glucose levels
(about 170–180 mg/dl), which remained stable during the
experimental period in untreated animals. These glycaemic
levels are consistent with previous results obtained by our
group and others in this diabetic model (Novelli et al. 2007;
Tahara et al. 2008). IAC was administered at various doses
(7.5, 15 or 30 mg/kg b.w./day) in diabetic mice and also in
a group of non-diabetic controls at 30 mg/kg b.w. In diabetic
mice, both IAC doses of 15 and 30 mg/kg significantly
decreased plasma glucose levels after 2–3w e e k so f
treatment, showing similar effectiveness. The lowest IAC
dose used(7.5 mg/kg b.w.)was only transiently effectiveand
was finally unable to significantly reduce hyperglycemia in
diabetic mice. No significant change in glycaemic values
was induced by IAC treatment in non-diabetic controls (not
shown). After 7 weeks of treatment, IAC administration was
discontinued, and glycaemia was periodically monitored for
additional 8 weeks. Interestingly, the correction of hyper-
glycaemia achieved with the IAC doses of 15 or 30 mg/kg b.
w. persisted after the suspension of the drug until the end of
the experiment.
Plasma insulin and nitrotyrosine levels Plasma insulin
levels, as measured 5 weeks after IAC treatment, were
significantly (p<0.05) decreased in untreated and 7.5 mg/
kg IAC-treated diabetic mice with respect to controls and
were improved in 15 and 30 mg/kg IAC-treated animals
[controls (C): 0.98±0.11 ng/ml; diabetics (D): 0.60±
0.07 ng/ml; D+7.5 mg/kg IAC: 0.60±0.08 ng/ml; D+
15 mg/kg IAC: 0.85±0.09 ng/ml, NS vs. C or D; D+
30 mg/kg IAC: 0.92±0.04 ng/ml, NS vs. C, p<0.05vs.D;
n=5–6 for each group].
We also measured plasma nitrotyrosine levels, which
are considered a valuable index of overall oxidative
stress (Ceriello et al. 2001), in untreated and treated
diabetic mice 5 weeks after IAC treatment. Confirming
previous results, we found that plasma nitrotyrosine
levels, significantly (p<0.05) increased in untreated and
7.5 mg/kg IAC-treated diabetic mice with respect to
controls, were partially restored during the antioxidant
treatment at the highest doses [controls (C): 0.68±0.09 µg/
ml; diabetics (D): 1.22±0.10 μg/ml; D+7.5 mg/kg IAC:
1.17±0.07 μg/ml; D+15 mg/kg IAC: 0.97±0.06 µg/ml,
NS vs. C or D; D+30 mg/kg IAC: 0.98±0.07 µg/ml, NS
vs. C or D; n=5 –6 for each group).
Glucose tolerance test An intraperitoneal glucose tolerance
test, performed in STZ-NA mice 6 weeks after IAC
treatment, showed that the severe glucose intolerance
observed in diabetic animals was partially and similarly
improved in the diabetic groups treated with IAC 15 and
30 mg/kg b.w. but not in the group treated with 7.5 mg/kg
b.w. (Fig. 3a). In IAC-treated mice, the 15-min post-loading
plasma insulin peak remained much lower than in healthy
controls but not as low as in the untreated diabetic group
(Fig. 3b). No significant alteration of insulin sensitivity was
observed in any experimental group during i.p. insulin
Fig. 2 Time course of glycaemic values in 3-h fasted control and
diabetic mice during IAC treatment and after its discontinuation. Mean ±
SEM of 10–12 mice for each group. C healthy controls, D STZ-NA
diabetic mice without pharmacological treatment, D+IAC 7.5 diabetic
mice treated with IAC 7.5 mg/kg b.w./day, D+IAC 15 diabetic mice
treated with IAC 15 mg/kg b.w./day; D+IAC 30 diabetic mice treated
with IAC 30 mg/kg b.w./day. Arrows indicate starting (+) and
discontinuation (−) of IAC treatment. Statistical analysis (ANOVA)
revealed significant differences between C and D; C and D+IAC 7.5,
15 and 30; D and D+IAC 15 and 30 (post hoc Tukey test)
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of IAC treatment (data not shown), consistently with
previous results (Novelli et al. 2007). Thus, the partial
improvement in glucose tolerance in mice treated with 15
and 30 mg/kg IAC should be ascribed to a slight/moderate
enhancement in the insulin response to the glucose load,
taking also into account that sampling at 15 min after the
load might not correspond to the real peak of insulin
secretion.
Quantitative immunohistochemical data At the end of the
experiment, immunohistochemical images of the pan-
creases from the various mice groups were submitted to
quantitative analysis using an improved image analysis
program, as detailed in “Materials and methods.” Repre-
sentative images of pancreatic sections of each group,
immunostained for insulin, are shown in Fig. 4. These high-
magnification images (×400) provide evidence of the
reduced insulin immunostaining in untreated diabetic islets
with respect to control islets. A reduced cell density is
apparent within the islets concomitantly with an increase of
intercellular space. Conversely, in IAC-treated diabetic
islets, density of cells and homogeneity of immunostaining
are clearly improved as compared to diabetic islets and
approach those of control islets. Morphometric analysis of
images at low magnification (×40) revealed that untreated
STZ-NA diabetic mice had a significant reduction in islet
number (−70%), relative β-cell area (−76%) and β-cell
mass (−76%) with respect to controls (Fig. 5a–c). IAC
treatment significantly reversed the decrease in all these
three parameters in a dose-related manner, although to a
different extent. Indeed, the beneficial effect of IAC
treatment was more attributable to preservation of β-cell
area than of islet number. In particular, both 15 and 30 mg/
kg IAC induced a clear-cut improvement with respect to
untreated diabetic mice, and the highest dose nearly
restored β-cell mass to the level of control mice.
Electron microscopy Pancreas specimens from control and
STZ-NA diabetic mice, untreated or treated with 30 mg/kg
Fig. 3 Glucose tolerance test in
control and IAC-treated diabetic
mice. Glycaemia and insulinae-
mia were determined during an
intraperitoneal glucose tolerance
test (glucose 1.5 g/kg) per-
formed after 6 weeks of IAC
treatment. Mean ± SEM of five
to six mice for each group.
Abbreviations are defined in
Fig. 2. The upper inset shows
the area under the curve (AUC)
for the glycaemic values; the
lower inset shows the percent
increase of 15-min post-loading
plasma insulin levels with re-
spect to the corresponding basal
value. *p<0.01 vs. the
corresponding controls;
§p<0.05
vs. the corresponding diabetics
(post hoc Tukey test)
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copy to study the ultrastructural alterations of pancreatic islets
(Fig. 6). In control mice, islets were quite large and
characterised by many β cells with abundant mature
granules. Nuclei were round and contained uncondensed
chromatin. Mitochondria, Golgi apparatus, and rough endo-
plasmic reticulum had a normal appearance. No apoptotic
cells or fibrosis could be detected. Conversely, in untreated
STZ-NA diabetic mice, islets were usually small and
contained β cells with reduced number of mature granules.
Many β-cell nuclei appeared deformed with clusters of
condensed chromatin behind the nuclear membrane. Mito-
chondria were numerous and often swollen, round in shape
and with dispersed cristae. A few apoptotic β cells were also
visible and some fibrosis occurred, as indicated by the
presence of collagen fibers both around and within several
islets (see Fig. 6, lower panels). Occasional deposits of
amyloid fibrils were detectable. Interestingly, in IAC-treated
diabetic mice, most of these changes did not occur, and islet
ultrastructure was very similar to that of controls. In
particular, β cells contained many mature granules; their
nuclei were round with normal loose chromatin, and
Fig. 4 Representative images of
pancreas sections immunos-
tained with an anti-insulin anti-
body. Pancreases were removed
and processed at the end of the
experiment, i.e. 8 weeks after
the end of IAC treatment. Mag-
nification ×400. Abbreviations
are defined in Fig. 2
Fig. 5 Islet number (a), relative β-cell area (b) and β-cell mass (c)i n
control and IAC-treated diabetic mice. These parameters were
evaluated on images at low magnification (×40) obtained after insulin
immunostaining, using an appropriate software, as described in
“Materials and methods.” Mean ± SEM of four to six mice for each
group. Abbreviations are defined in Fig. 2
132 Naunyn-Schmied Arch Pharmacol (2010) 382:127–137mitochondria appeared elongated with parallel cristae.
Apoptosis and fibrosis were not observed. Several islets
were located in close proximity to blood vessels.
Morphometric analysis revealed that both number and
volume density of mature granules were significantly reduced
in βcells of STZ-NA diabetic mice withrespect to controls and
that IAC (30 mg/kg b.w.) treatment fully reversed these
changes (Table 1). Moreover, in β cells of STZ-NA diabetic
mice, both number and volume density of mitochondria were
significantly increased with respect to controls, and IAC
treatment restored both parameters to almost normal values
(Table 1).
Discussion
It is increasingly being realized that T2D develops in insulin-
resistant subjects when pancreatic β cells fail to secrete
sufficient insulin to compensate for insulin resistance (Kahn
2003;K a s u g a2006). This failure ultimately leads to hyper-
glycaemia, which can in turn further impair β-cell secretory
effectiveness and/or progressively reduce β-cell mass (Butler
et al. 2003; Rhodes 2005; Robertson 2004;W a r de ta l .
1984). Among the various mechanisms potentially involved
in hyperglycaemia-linked β-cell dysfunction and diabetes
progression, chronic oxidative stress is recognized to play a
major role (Brownlee 2003; Kaneto et al. 2005;R o b e r t s o n
2004; Robertson et al. 2004). Oxidative stress refers to a
persistent imbalance between excessive production of ROS
and/or RNS and limited antioxidant defence. Pancreatic β
cells are especially susceptible to this event, as they lack
robust protection against toxicity of free radicals (Tiedge et
al. 1997). Hyperglycemia can lead to increased radical
generation in β-cells by a variety of mechanisms, including
accelerated glycolytic flux and pyruvate feeding to the
tricarboxylic acid cycle (Brownlee 2003), mitochondrial
fragmentation (Men et al. 2009), enhanced rate of alternative
Fig. 6 Representative electron
microscope images of pancreatic
β cells from control (C), un-
treated (D) and 30 mg kg
−1
day
−1 IAC-treated (D + IAC)
diabetic mice. Specimens from
pancreases removed 8 weeks
after the end of IAC treatment
were fixed with 2.5% glutaral-
dehyde and processed for EM
analysis, as detailed in “Materi-
als and methods.” Upper panels
(magnification, ×10,000): M
with white arrows indicates mi-
tochondria. Lower panels (mag-
nification, ×16,000): evidence of
an apoptotic β cell (asterisk)
and collagen fibrils (black
arrows) in diabetic mice, and a
detail of a well granulated
healthy β cell with a neighbor α
cell (at the upper right corner)
in IAC-treated animals
Table 1 Ultrastructural morphometric analysis of mature insulin granules and mitochondria in pancreatic beta cells from control (C), untreated
diabetic (D) and IAC-treated diabetic (D+IAC 30) mice, 8 weeks after the end of IAC treatment (30 mg/kg b.w.)
Mature insulin granules Mitochondria
Number/area unit Volume density (ml) Number/area unit Volume density (ml)
C 167.5±25.2 14.5±2.30 9.3±2.21 3.1±0.62
D 76.2±2.7* 6.8±1.25* 17.6±2.11* 7.8±0.42*
D+IAC 30 151.4±8.7** 10.5±0.80** 10.6±2.89 3.6±0.77**
Mean ± SEM of 9–12 determinations for each group. Area unit was 70 μm
2
*p<0.05, at least, vs. C; **p<0.05, at least, vs. D (Student’s t test)
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(Robertson 2006), activation of NF-kB pathway and conse-
quent induction of iNOS and production of inflammatory
cytokines (Maedler et al. 2002), which in turn can increase
intracellular ROS and NO generation (Eizirik and Mandrup-
Poulsen 2001). This overproduction of ROS/RNS may have
severe cytotoxic effects on β-cell structures through protein
oxidation, membrane lipid peroxidation and DNA damage
(Beckman and Koppenol 1996; Ceriello 2003). Furthermore,
oxidative stress may impair the transcription of the insulin
gene and other relevant β-cell genes by interfering with the
transcriptional activity of the pancreatic and duodenal
homeobox factor-1 PDX-1 (Kaneto et al. 2006). Thus, a
pharmacological approach for treatment of diabetes based on
the use of low molecular weight antioxidants able to exert a
prolonged ROS/RNS scavenging activity, possibly at sites of
radical production like mitochondria, appears highly advis-
able (Ceriello 2003; Maritim et al. 2003;M u r p h ya n dS m i t h
2007; Soule et al. 2007).
On the basis of a previous diabetes model with reduced
β-cell mass established in rats using diabetogenic doses of
STZ and partially protective doses of NA (Masiello et al.
1998), we and others have developed an analogous model
in C56Bl/6J mice (Masiello et al. 2006;M a t s u y a m a -
Yokono et al. 2008; Nakamura et al. 2006). STZ-NA-
treated mice develop a non-obese diabetic syndrome
characterised by moderate and stable hyperglycaemia,
hypoinsulinaemia, growth impairment, and approximately
75% reduction of pancreatic insulin stores. In this model,
we have previously shown that the non-conventional
radical scavenger IAC, a “palindromic” nitroxide com-
pound in its reduced hydroxylamine form (see Fig. 1),
synthesised in our laboratories, improves diabetic metabolic
alterations by counteracting β-cell dysfunction associated
with oxidative stress (Novelli et al. 2007). A major aim of
the present research was to verify whether the beneficial
effect of IAC administration could be protracted after
suspension of the treatment. Our results confirm that IAC
treatment (at doses of 15 or 30 mg/kg b.w., but not 7.5 mg/
kg b.w.) was able to decrease hyperglycaemia and improve
glucose tolerance, meanwhile partially reducing plasma
nitrotyrosine levels, an overall index of oxidative stress,
which was increased twofold in diabetic mice, similarly to
what has been reported in type 2 diabetic patients (Ceriello
et al. 2001, 2004). Very interestingly, the correction of
hyperglycaemia still persisted in STZ-NA diabetic mice
8 weeks after IAC discontinuation. With regard to the
mechanism of the long-term beneficial effect of IAC
treatment, we hypothesised that this improvement could
be dependent on preservation of β-cell mass. To directly
test this hypothesis, in the present study, we have measured
β- c e l lm a s so nt h eb a s i so fa ni m p r o v e dm e t h o do f
morphometric analysis of pancreatic sections immunos-
tained for insulin. Such analysis revealed that untreated
STZ-NA mice had a 70–80% reduction of islet number,
relative β-cell area and β-cell mass with respect to controls
and that a daily IAC treatment for 7 weeks prevented these
changes in a dose-related manner, although administration
of the compound was suspended for several weeks prior to
analysis. To our knowledge, only another non-peptidyl
antioxidant compound, N-acetyl-cysteine, when combined
with vitamins C and E, was able to partially reduce basal
hyperglycaemia and improve β-cell mass in a mouse model
of T2D (Kaneto et al. 1999). Actually, effective scavengers
of both ROS and NRS have also been reported to prevent
diabetes development in NOD mice, a well-known model
of autoimmune type 1 diabetes (Olcott et al. 2004) or other
autoimmune diseases like experimental encephalomyelitis
(Malfroy et al. 1997). Furthermore, such scavengers,
including IAC itself, have been shown to decrease tissue
damage in experimentally induced colitis in rats (Cuzzocrea
et al. 2000; Vasina et al. 2009) or in post-ischemic brain in
Mongolian gerbils (Canistro et al. 2010), thereby confirm-
ing their beneficial effects in several pathological situations
in which inflammation- or reperfusion-derived oxidative
stress is supposed to play a major role.
Our data support the hypothesis that the remarkable
decrease in β-cell mass found in untreated diabetic mice at
the end of the experimental period (i.e. 18 weeks after
induction of diabetes) is not only dependent on the acute β-
cell destruction induced by STZ but also on the further β-
cell loss due to the oxidative stress-induced apoptosis
associated with chronic hyperglycaemia (Kim et al. 2005;
Maedler et al. 2002). It is this additional β-cell loss that is
probably prevented by IAC treatment, resulting in better
preservation of islet number and islet β-cell core, as shown
by our immunohistochemical data, which would explain the
long-term correction of hyperglycaemia even after discon-
tinuation of the treatment. These results are consistent with
the observation that in isolated human islets, IAC prevented
FFA-induced oxidative stress as well as reduction of β-cell
viability and increase in the pro-apoptotic BAX/BCL-2
ratio (D'Aleo et al. 2009). However, it should be noticed
that despite the improvement in β-cell mass, IAC-treated
diabetic animals do not achieve full normalisation of
glycaemia and glucose tolerance, suggesting that rescued
β cells still hold some functional defect.
The prevention of mitochondrial alterations in β cells of
IAC-treated diabetic mice, as shown by ultrastructural
morphometric analysis, appears of particular interest. It
has been recently documented that both β-cell dysfunction
and increased mitochondrial superoxide levels induced by
prolonged glucose infusion in vivo are fully prevented by
treatment with the superoxide dismutase mimetic TEMPOL
(Tang et al. 2007), a nitroxide radical structurally related to
IAC. Actually, it is likely that IAC would better accumulate
134 Naunyn-Schmied Arch Pharmacol (2010) 382:127–137into mitochondria and would exert a stronger antioxidant
effect than TEMPOL, due to its better membrane perme-
ability conferred by the long aliphatic chain connecting the
two cyclic hydroxylamine moieties. Furthermore, the nitro-
xide derived from IAC interaction with radicals would be
rapidly reconverted to hydroxylamine with regeneration of
the scavenging activity (Valgimigli et al. 2001). At this
regard, it is worthwhile to mention that a mitochondria-
targeted form of TEMPOL (mito-TEMPOL) was recently
shown to be selectively taken up by mitochondria and here
reduced to mito-TEMPOL-H, i.e. to its hydroxylamine, by
mitochondrial ubiquinol (Trnka et al. 2008). Interestingly,
mito-TEMPOL-H holds a remarkable antioxidant activity
and is more effective at preventing lipid peroxidation than
TEMPOL itself (Trnka et al. 2009).
Besides their central role in the control of insulin
secretion, mitochondria may also contribute to the regula-
tion of β-cell mass. The available data suggest that
increased apoptosis underlies the loss of β-cell mass in
type 2 diabetic patients (Butler et al. 2003). Mitochondria
might well play a major role in this process, as they are
involved in the regulation of cell apoptosis by multiple
mechanisms (Jeong and Seol 2008). It is presently
recognised that mitochondria are characterised by a
remarkable plasticity (mitochondrial network), as their
number and morphology are highly regulated through
mitochondrial fusion and fission processes in response to
physiological requirements or pathological stimuli (Detmer
and Chan 2007; Jeong and Seol 2008; Wikstrom et al.
2007). With regard to hyperglycaemia and related enhanced
ROS production, evidence is being accumulating that
mitochondrial fragmentation by fission occurs under these
circumstances and may lead to apoptosis through cytoc-
rome c release into the cytosol (Men et al. 2009; Yu et al.
2008). At present, very little information is available on the
ultrastructural alterations of β-cell mitochondrial in diabe-
tes, apart from the increase in mitochondrial volume density
observed by Anello et al. (2005) in islets isolated from type
2 diabetic donors. In β cells of STZ-NA diabetic mice, as
compared to controls, we observed a significant increase in
not only volume density of mitochondria due to their
altered shape and swelling but also their number, likely as a
consequence of increased fission events (Chan 2007).
Interestingly, both alterations were corrected by IAC
treatment, consistently with the possibility that this com-
pound can indeed prevent mitochondrial fragmentation and
rescue β cells from apoptotic outcome. Of course, further
studies are needed to directly assess the influence of IAC
on the molecular factors involved in mitochondrial dynam-
ics and remodeling (Kuznetsov et al. 2009).
In conclusion, our study confirms that the radical
scavenger IAC improves metabolic alterations in STZ-NA
diabetic mice and shows that this improvement persists for
a long time after discontinuation of IAC treatment, likely
due to partial correction of β-cell dysfunction and preven-
tion of β-cell loss induced by hyperglycaemia-linked
oxidative stress. Furthermore, our ultrastructural data
suggest that mitochondria could be a major site of the
protective action of IAC in pancreatic β cells. Altogether,
these findings reinforce the notion that antioxidant agents
such as IAC may have a relevant therapeutic potential in
diabetes.
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